2021
DOI: 10.1111/ijd.15704
|View full text |Cite
|
Sign up to set email alerts
|

A case of moderate hidradenitis suppurativa and psoriasis successfully treated with risankizumab

Abstract: undetected primary gonadal GCT which may have regressed spontaneously, especially a testicular tumor. [1][2][3] Primary and metastatic (also called secondary) germ cell tumors account for approximately one quarter of all retroperitoneal tumors. 2,3 For both primary and secondary tumors, serum tumor marker detection could help with diagnosis (e.g., alpha-fetoprotein, human chorionic gonadotropin), as well as they are markers of tumor relapse. 2,3 However, the existence of the so-called primary EGCT of the retro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
19
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 18 publications
(20 citation statements)
references
References 7 publications
0
19
1
Order By: Relevance
“…Anti-IL 23 drugs (guselkumab, risankizumab, tildrakizumab) represent the latest class of biologics approved for the treatment of moderate to severe psoriasis [ 43 , 44 , 45 , 46 ]. To date, the efficacy and safety of anti-IL 23 in the management of HS have been described only in some case series, showing contrasting results [ 47 , 48 , 49 , 50 ]. Indeed, the precise role of IL 23 in HS is not yet fully understood.…”
Section: Resultsmentioning
confidence: 99%
“…Anti-IL 23 drugs (guselkumab, risankizumab, tildrakizumab) represent the latest class of biologics approved for the treatment of moderate to severe psoriasis [ 43 , 44 , 45 , 46 ]. To date, the efficacy and safety of anti-IL 23 in the management of HS have been described only in some case series, showing contrasting results [ 47 , 48 , 49 , 50 ]. Indeed, the precise role of IL 23 in HS is not yet fully understood.…”
Section: Resultsmentioning
confidence: 99%
“…After 3 months of therapy, HiSCR was achieved by both female patients and the male patient presented a complete clinical response of both diseases 16 weeks after starting risankizumab. No serious adverse events were reported (only one mild adverse event occurred: an episode of tonsillitis) [254,255].…”
Section: Risankizumabmentioning
confidence: 99%
“…Three publications report clinical response to risankizumab in four patients treated at psoriasis doses (150 mg sc at week 0, week 4, and every 12 weeks thereafter). [184][185][186] A phase II, double-blind RCT to evaluate the safety and efficacy of two dose levels of risankizumab in adult patients with moderate-to-severe HS is being conducted (NCT03926169). 187 Tildrakizumab is a humanized monoclonal antibody that targets the p19 subunit of IL-23.…”
Section: Surgerymentioning
confidence: 99%